Anat Cohen-Dayag, Ph.D.

President and CEO

Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry in Israel, both in R&D and executive leadership roles. Dr. Cohen-Dayag joined Compugen in 2002, and has held various positions with increasing responsibilities, including VP Diagnostic Biomarkers & Drug Targets and VP R&D, before being appointed President and CEO in 2010. Under her leadership, Compugen transformed from a service provider in the field of computational biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline originating from the Company’s computational discovery platforms. In 2014, Dr. Cohen-Dayag also joined Compugen’s board of directors. Dr. Cohen-Dayag joined Compugen from Mindsense Biosystems Ltd. where she served as Head of R&D and was a member of the executive management team. Dr. Cohen-Dayag holds a B.Sc. in Biology from Ben-Gurion University, and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science.

Ari Krashin

Chief Financial and Operating Officer

Mr. Krashin joined Compugen in 2014 as Chief Financial Officer of Compugen. In 2016, he was appointed also Chief Operating Officer. Mr. Krashin has over 15 years of experience in capital markets, finance and business development. He served as a chief financial officer for both public and private companies, the most recent being AnyClip Media and Spacenet Inc. Mr. Krashin was also the CFO of Gilat Satellite Networks where he led the company's global finance and related operations, including business development, M&A activities, investor relations and administration. Mr. Krashin is a certified public accountant and began his professional career with Kesselman and Kesselman, PWC, Israel. Mr. Krashin holds a B.A. in Business Administration and Accounting from the College of Management, Rishon Le’Zion.

Henry Adewoye, MD

Senior Vice President and Chief Medical Officer

Dr. Adewoye joined Compugen in March 2018 as Chief Medical Officer, bringing to Compugen over 20 years of extensive experience in leading multiple clinical trials in Oncology and Hematology in both the biopharmaceutical industry and academia. Before Compugen, Dr. Adewoye was with Gilead Sciences Inc., as Clinical Director in Oncology Clinical Research and was on the Oncology Leadership Team. He most recently served as Project Team and Clinical Lead for Idelalisib (first-in-class PI3K delta inhibitor approved for the treatment of relapsed CLL, FL/SLL) and Andecaliximab (MMP9 mAb inhibitor). Previously, he was Clinical Research Medical Director in Oncology at Amgen Inc. Dr. Adewoye was the Global Medical Monitor for the initial registrational trial of the bispecific antibody blinatumomab (Blincyto®) and several Phase 2 and 3 studies evaluating VEGF inhibitors (Motesanib, Trebananib) in patients with solid tumors. Dr. Adewoye completed his Fellowship in Hematology/Oncology at Boston Medical Center and completed his residency in Internal Medicine at Meharry Medical College. Dr. Adewoye received his medical degree at the University of Jos, Nigeria and Fellowship training in Hematology and Laboratory medicine at the University College Hospital Ibadan, Nigeria. Dr. Adewoye is Board Certified by the American Board of Internal Medicine in Medical Oncology, Hematology and Internal Medicine.

Oliver Froescheis, Ph.D.

Senior Vice President, Corporate and Business Development

Dr. Froescheis joined Compugen in January 2020 as Senior Vice President, Business and Corporate Development. Dr. Froescheis brings to Compugen over 20 years of experience in the pharmaceutical industry where he held positions in research, project management, marketing and business development. Dr. Froescheis joins Compugen from Roche, where he spent the last 12 years in the Partnering organization, initially serving as Global Due Diligence Director for in-licensing and M&A projects, then acting as Director of Business Development & Licensing, responsible for oncology/immuno-oncology partnering projects and most recently leading R&D out-licensing across therapeutic areas. Dr. Froescheis holds a Diploma in Chemistry and a Ph.D. in Analytical Chemistry, both from the University of Ulm, Germany.

Eran Ophir, Ph.D.

Vice President, Research and Drug Discovery

Dr. Eran Ophir joined Compugen in 2015 and was appointed Vice President of Research and Drug Discovery in March 2020. In his role, Dr. Ophir is responsible for the Company’s Research and Drug Discovery activities, overseeing the research into the biology of the Company’s computationally discovered targets and therapeutic lead identification and selection. Dr. Ophir brings to Compugen significant expertise in immunology and immuno-oncology from his research work at the Weizmann Institute of Science and post-doctoral fellowship at the Ludwig Institute for Cancer Research in Lausanne, Switzerland. Dr. Ophir joined Compugen’s immuno-oncology group as a senior scientist and has since held various positions in the Research and Development department, with increasing responsibilities. Dr. Ophir received a B.Sc. in Bioinformatics from Tel Aviv University and a Ph.D. in Biology from the Weizmann Institute of Science.

Zurit Levine, Ph.D.

Senior Vice President, Technology Innovation

Dr. Levine was appointed Senior Vice President, Technology Innovation in October 2018, responsible for leading and advancing the Company’s computational innovation towards new discovery fields and areas. In this capacity Dr. Levine is also responsible for Compugen’s IP strategy and portfolio. Dr. Levine joined Compugen in 1999 and has held several positions in Compugen’s Research & Development department. In 2004, she was appointed Director of Therapeutic Selection & Validation, which position she held until 2007 when she was appointed Director of Therapeutic Discovery. In 2009, she was appointed Executive Director of Research & Development. From January 2010 to August 2011, she held the position of Vice President, Research and Development. In August 2011 she was appointed Vice President, Research and Discovery. Dr. Levine holds a B.Sc. in Biology, a M.Sc. in Biochemistry and a Ph.D. in Biochemistry, all from the Tel Aviv University.

Yaron Turpaz, Ph.D.

Senior Vice President and Senior Advisor, Computational Discovery

Dr. Turpaz joined Compugen in November 2019 as Senior Vice President and Senior Advisor, Computational Discovery. Dr. Turpaz has over 15 years of experience in the fields of research and development informatics, data sciences and technology in the biotech and pharma space with hands on experience using cloud based high throughput computational, machine learning and genomics platforms for drug discovery and development applications in precision medicine. In his extensive pharma and biotech career, he held senior R&D Informatics roles at Human Longevity Inc, AstraZeneca, Eli Lilly and Affymetrix. Dr. Turpaz will continue to lead data science and technology at Global Gene Corp. and serve as Chief Information Officer and Senior Advisor at Engine Biosciences. Dr. Turpaz received a B.Sc. in Biology from Tel Aviv University, a Ph.D. in Bioengineering from the University of Illinois and an MBA from the University of Chicago, Booth School of Business. He also held an Adjunct Assistant Professor position at the Centre for Quantitative Medicine of Duke-National University of Singapore, Graduate Medical School.

Dorit Amitay

Vice President, Human Resources

Dorit Amitay joined Compugen’s human resources department in 1999, bringing with her over ten years of experience. During her tenure at the Company, Ms. Amitay took on increasingly larger roles in the HR department until assuming her current position in 2007. Prior to joining Compugen, Ms. Amitay worked for one of the leading Israeli recruitment and placement agencies. Ms. Amitay holds a B.A. in Social Sciences and an MBA, both from Ben Gurion University in Israel and an M.A. in Organizational Consulting and Development from The College of Management Academic Studies.